Thomas de Vlaam
Private Equity Investor chez Pillar Co Management LLC
Profil
Mr. Thomas de Vlaam is a Partner at Pillar Co Management LLC.
Mr. de Vlaam was previously employed as a Founder & CEO by Amylon Therapeutics BV.
He received his undergraduate degree from the University of Groningen.
Postes actifs de Thomas de Vlaam
Sociétés | Poste | Début |
---|---|---|
Pillar Co Management LLC
Pillar Co Management LLC Investment ManagersFinance Pillar Co Management LLC (Pillar VC) is a venture capital firm founded in 2016 by Jamie Goldstein. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/07/2022 |
Anciens postes connus de Thomas de Vlaam
Sociétés | Poste | Fin |
---|---|---|
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Directeur Général | 31/05/2022 |
Formation de Thomas de Vlaam
University of Groningen | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Pillar Co Management LLC
Pillar Co Management LLC Investment ManagersFinance Pillar Co Management LLC (Pillar VC) is a venture capital firm founded in 2016 by Jamie Goldstein. The firm is headquartered in Boston, Massachusetts. | Finance |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |